Nyxoah (NASDAQ:NYXH) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Nyxoah (NASDAQ:NYXH) to a hold rating in a research report sent to investors on Saturday.

A number of other equities analysts have also commented on NYXH. Piper Sandler reaffirmed an “overweight” rating and set a $7.00 price target (down from $9.00) on shares of Nyxoah in a research report on Wednesday, May 13th. Weiss Ratings lowered shares of Nyxoah from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 22nd. Robert W. Baird set a $2.85 price target on shares of Nyxoah in a research report on Thursday, July 9th. Finally, Stifel Nicolaus cut their price target on Nyxoah from $5.00 to $3.00 and set a “hold” rating for the company in a research note on Wednesday, June 17th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Nyxoah presently has a consensus rating of “Hold” and an average price target of $5.96.

Nyxoah Stock Performance

NASDAQ:NYXH opened at $1.46 on Friday. The stock has a 50 day simple moving average of $1.77 and a 200 day simple moving average of $3.03. The stock has a market cap of $56.59 million, a P/E ratio of -0.59 and a beta of 1.62. Nyxoah has a 1-year low of $1.26 and a 1-year high of $8.59. The company has a current ratio of 0.99, a quick ratio of 0.88 and a debt-to-equity ratio of 0.53.

Nyxoah (NASDAQ:NYXH) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.43) EPS for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.11. The firm had revenue of $7.38 million for the quarter, compared to analyst estimates of $7.05 million. Nyxoah had a negative return on equity of 163.73% and a negative net margin of 543.21%. Research analysts anticipate that Nyxoah will post -1.67 earnings per share for the current year.

Institutional Investors Weigh In On Nyxoah

Large investors have recently bought and sold shares of the company. Bank of America Corp DE boosted its holdings in shares of Nyxoah by 72.4% in the 2nd quarter. Bank of America Corp DE now owns 7,866 shares of the company’s stock valued at $59,000 after purchasing an additional 3,303 shares in the last quarter. Raymond James Financial Inc. raised its holdings in shares of Nyxoah by 35.6% during the 3rd quarter. Raymond James Financial Inc. now owns 12,762 shares of the company’s stock worth $59,000 after buying an additional 3,353 shares in the last quarter. Deutsche Bank AG lifted its position in shares of Nyxoah by 40.0% during the 4th quarter. Deutsche Bank AG now owns 35,000 shares of the company’s stock worth $161,000 after buying an additional 10,000 shares during the last quarter. Citadel Advisors LLC bought a new stake in shares of Nyxoah during the 3rd quarter worth $98,000. Finally, Shay Capital LLC acquired a new stake in Nyxoah in the second quarter valued at about $374,000.

About Nyxoah

Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.